Therapeutic Applications Of Mesenchymal Stem Cells - Advances, Products & Technologies

Researchmoz added Most up-to-date research on "Therapeutic Applications Of Mesenchymal Stem Cells - Advances, Products & Technologies" to its huge collection of research reports.

This global strategic report is produced for:

Management of stem cell companies
Management of regenerative therapy companies
Stem cell industry investors
It is designed to increase your efficiency and effectiveness in:
Commercializing mesenchymal stem cell (MSC) products, technologies, and therapies
Making intelligent investment decisions
Launching high-demand products
Selling effectively to your client base
Increasing revenue from MSC products and services
Taking market share from your competition

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.

MSCs are advantageous over other stem cells types for a variety of reasons: they avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs reduce both the risks of rejection and complications of transplantation. Recently, there have been advances in the use of autologous mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, bone fractures, and more.

This global strategic report explores recent advances in MSC research applications, research priorities by market segment, and the competitive environment for MSC research products. It also identifies trend and growth patterns within the MSC industry. Because it is important for pharmaceutical companies interested to understand underlying forces affecting the MSC market, this report also presents a range of topics that apply to these companies, including how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=301052

Clinical Progress with MSCs

As mentioned, mesenchymal stem cells (MSCs) have inspired a lot of activity over the past ten years as a novel therapeutic model for a wide range of diseases. Presently, MSCs-based clinical trials are being conducted for twelve types of disease conditions, with many completed trials showing their safety and efficacy.

The clinical utility of MSCs are mostly attributed to their four key biological properties, which are their potential to:
Migrate to sites of inflammation caused by tissue injury when injected intravenously
To get differentiated into different cell types
To release different bioactive molecules having the potential of stimulating recovery of injured cells and preventing inflammation
To accomplish immunomodulatory functions

Currently, there are 128 clinical trials involving MSCs are in progress in different parts of the world, including China, the European Union, the United States, the Middle East, and South Korea. Among these trials, 45 (35%) are exploiting MSCs for various disease indications. Currently, four major clinical trials using MSCs have reached Phase III. Stempeutics Research’s product candidate Stempeucel is being evaluated in two centers for treating critical leg ischemia. Prochymal is the product candidate from Osiris Therapeutics and it is being used for treating graft vs. host disease (GvHD). The company is also testing Prochymal for treating Crohn’s disease in another Phase III trial. The Australian company Mesoblast is testing an ‘off-the-shelf’ mesenchymal precursor product candidate for treating patients with hematological malignancies.

Report Objectives

The purpose of this report is to describe the current status of mesenchymal stem cells (MSCs) research, the ongoing clinical trials involving MSCs, late stage MSCs clinical trials, and the possible uses of MSCs in cell therapy. As MSC cell therapy is an integrated component of other cell therapies and regenerative medicines (RM), the report also gives a brief overview of the RM industry and overall cell therapy (CT) industry.

Thus, the main objectives are to consider the following:

Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular.
Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells.
Current status of MSCs in clinical trials, the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types.
The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their sustained search for MSCs-based cell therapy products.

Key questions answered in this global strategic report are:

How many companies are currently supporting the RM industry?
What is the current regional breakdown of RM industry?
How many RM products have been approved?
What are the types of diseases are currently being pursued by RM companies?
What are the major financial events, partnerships and acquisitions in RM sector?
How do the large pharma companies perceive the value and long-term prospects of RM and CT?

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=301052

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

This release was published on openPR.